This approach has subsequently been used in a Phase II trial (NCT03544723) investigating safety and efficacy of p53 gene therapy combined with immune checkpoint inhibitors in solid tumours including HNSCC [142]. Here, TP53 is linked to head and neck squamous cell carcinoma.